1. Home
  2. GAUZ vs PBYI Comparison

GAUZ vs PBYI Comparison

Compare GAUZ & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GAUZ
  • PBYI
  • Stock Information
  • Founded
  • GAUZ 2009
  • PBYI 2010
  • Country
  • GAUZ Israel
  • PBYI United States
  • Employees
  • GAUZ N/A
  • PBYI N/A
  • Industry
  • GAUZ Industrial Machinery/Components
  • PBYI Biotechnology: Pharmaceutical Preparations
  • Sector
  • GAUZ Miscellaneous
  • PBYI Health Care
  • Exchange
  • GAUZ Nasdaq
  • PBYI Nasdaq
  • Market Cap
  • GAUZ 102.0M
  • PBYI 171.7M
  • IPO Year
  • GAUZ 2024
  • PBYI N/A
  • Fundamental
  • Price
  • GAUZ $5.47
  • PBYI $4.52
  • Analyst Decision
  • GAUZ Strong Buy
  • PBYI Strong Buy
  • Analyst Count
  • GAUZ 3
  • PBYI 1
  • Target Price
  • GAUZ $13.67
  • PBYI $7.00
  • AVG Volume (30 Days)
  • GAUZ 58.8K
  • PBYI 592.1K
  • Earning Date
  • GAUZ 11-11-2025
  • PBYI 11-06-2025
  • Dividend Yield
  • GAUZ N/A
  • PBYI N/A
  • EPS Growth
  • GAUZ N/A
  • PBYI 434.29
  • EPS
  • GAUZ N/A
  • PBYI 0.97
  • Revenue
  • GAUZ $96,810,000.00
  • PBYI $238,062,000.00
  • Revenue This Year
  • GAUZ $23.16
  • PBYI N/A
  • Revenue Next Year
  • GAUZ $40.82
  • PBYI N/A
  • P/E Ratio
  • GAUZ N/A
  • PBYI $4.65
  • Revenue Growth
  • GAUZ 7.87
  • PBYI 8.63
  • 52 Week Low
  • GAUZ $4.54
  • PBYI $2.32
  • 52 Week High
  • GAUZ $13.00
  • PBYI $6.07
  • Technical
  • Relative Strength Index (RSI)
  • GAUZ 44.55
  • PBYI 51.02
  • Support Level
  • GAUZ $5.19
  • PBYI N/A
  • Resistance Level
  • GAUZ $6.00
  • PBYI $5.22
  • Average True Range (ATR)
  • GAUZ 0.33
  • PBYI 0.24
  • MACD
  • GAUZ 0.09
  • PBYI -0.28
  • Stochastic Oscillator
  • GAUZ 63.70
  • PBYI 83.09

About GAUZ Gauzy Ltd. Ordinary Shares

Gauzy Ltd is a fully integrated light and vision control company. Its products include suspended particle device and liquid crystal materials for smart glass applications and AI-powered driver assistance systems, or ADAS, solutions including camera monitoring systems. The company's operating segments are Architecture, Automotive, Safety tech, and Aeronautics. Maximum revenue is generated from its Safety tech segment, which focuses on sales of driver assistance systems for buses, coaches, recreational vehicles, and specific vehicles, such as camera and motion sensor systems, smart mirrors, and safety doors. Geographically, it derives maximum revenue from other European countries (excluding France), followed by the United States, France, Asia, Israel, and other regions.

About PBYI Puma Biotechnology Inc

Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

Share on Social Networks: